Compositions of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. These compositions may find particular use as anti-bacterial and in some variations anti-viral, anti-fungal and anti-cancer compositions.

The present invention relates to hydrogels that include native skin components, as well as to bio-inks, compositions and dressings based on the same. Furthermore, the invention relates to their uses in regenerative medicine, in particular, in the regeneration, repair and replacement of skin tissue, and a method for obtaining the hydrogels of the invention.

Generally, the invention is in relation to the field of drug delivery devices to augment standard radiation therapy and methods of making and using same. Specifically, this technology utilizes a controlled release of drug from a coated balloon for local intratumoral drug delivery to breast tissue to supplement or replace standard radiation therapy.

The present disclosure relates to halogenated fatty acid lactylates, in particular to chlorinated fatty acid lactylates.

The halogenated fatty acid lactylates now disclosed have antimicrobial and/or antibiofilm activity towards healthcare associated microbial infections.

Farnesol analogs, along with their related products (e.g., treatment compositions, wipes, absorbent articles, etc.) and their methods of formation, are provided. The farnesol analog includes a hydrophilic end group (e.g., a hydroxyl end group or a carboxylic acid end group) attached to farnesol via a covalent linkage (e.g., an ester group or an ether group).

Compositions and emulsions are described, which are useful in treating disease.

The present disclosure relates to a hydrogel comprising: hyaluronic acid, and liposomes physically crosslinked to hyaluronic acid, wherein said hydrogel encapsulates a cell type or a plurality of cell types. The hydrogel of the present disclosure shows a positive therapeutic effect in the treatment or therapy of multiple sclerosis. A pharmaceutical composition comprising a therapeutically effective amount of a hydrogel and a pharmaceutically acceptable excipient/carrier are also disclosed.

Compositions including a complex of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. In particular, described herein are compositions of decanoic acid:Arginine in which the decanoic acid and Arginine for a complex having a lamellar supramolecular structure.

The present invention generally relates to nitric oxide releasing pharmaceutical compositions and methods of using the same.

The present invention relates to a coating composition for an in-vivo implantable prosthesis including a photoinitiator, a crosslinking agent, and a phosphorylcholine (PC) monomer having an acrylate group, a method of coating an in-vivo implantable prosthesis using the coating composition, and a cosmetic prosthesis coated with the crosslinked polyphosphorylcholine. An in-vivo implantable prosthesis coated with crosslinked polyphosphoryicholine may be manufactured by a simple method of applying a coating composition including a photoinitiator, a crosslinking agent, and a phosphorylcholine (PC) monomer having an acrylate group according to the present invention, and then irradiating UV rays. The crosslinked polyphosphorylcholine coating may provide hydrophilicity for the surface and may also remarkably reduce adsorption of proteins and fibroblasts, which may cause side effects such as capsular contracture. Further, the coating has strong enough not to peel off even under stimulation, and therefore, it is maintained under vigorous activity after implantation, thereby being usefully applied to the manufacture of an in-vivo implantable prosthesis with reduced side effects, such as breast prosthesis for cosmetic surgery.